The public is hereby informed that the Food and Drug Administration (FDA) has conducted sampling of specific batches of BRAVO Maca + Jatropha + Corynaea Crassa Food Supplement for Men as part of the strengthened post-marketing surveillance of this Office.
The analyses of the FDA Laboratory showed that the abovementioned product with the following lot numbers tested positive for Tadalafil:
| Lot number | Expiry date |
| ABV38M23W | 23 March 2024 |
| ABV38Y04W | 04 May 2024 |
Tadalafil is a prescription drug used to treat male sexual function problems such as impotence or erectile dysfunction (ED).
Tadalafil is prohibited in food supplements, since it poses potential health risks to the unwary consuming public especially those who have had a stroke, persons experiencing stomach ulcers, heart problems, kidney problems, bleeding problem, blood cell problems, and low or high blood pressure. Possible side effects which can occur are as follows:
- indigestion
- muscle aches
- flushing
- nausea
- back pain
- stuffy or runny nose
- headaches
The presence of drug ingredient Tadalafil deems the food supplement as ADULTERATED, which is in violation of R.A. 9711 (FDA Act of 2009) and R.A. 10611, otherwise known as the Food Safety Act of 2013.
Consumers are advised to:
1. Stop taking BRAVO Maca + Jatropha + Corynaea Crassa Food Supplement for Men with lot numbers ABV38M23W and ABV38Y04W.
2. Consult a healthcare professional in case you experience any of the side effects upon consumption of the product.
3. Exercise caution when purchasing food supplements for men that can be potentially adulterated with drug ingredients which can seriously harm the consumers.
All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that the said products are not sold or made available concerned distributors, after the issuance of this advisory, in their localities or areas of jurisdiction.
To report continuous sale or distribution of the above adulterated food supplement, utilize our online reporting facility, eReport, at [email protected]
Dissemination of the information to all concerned is requested.